A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo

Purpose: To investigate the efficacy and mechanism of compound 23, a PI3K/HDAC dual-target inhibitor, on hematologic tumor cells in vitro and in vivo. Methods: The MTS Kit was used to study the antiproliferative effects in vitro. Western blot was used to analyze the involved signaling pathways. Flow...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zheng, Zhang, Kehui, Ji, Ming, Xu, Heng, Chen, Xiaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519310/
https://www.ncbi.nlm.nih.gov/pubmed/34658878
http://dx.doi.org/10.3389/fphar.2021.741697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519310/
https://www.ncbi.nlm.nih.gov/pubmed/34658878
http://dx.doi.org/10.3389/fphar.2021.741697

Ejemplares similares